10 October 2019 - The company also announced today that the U.S. FDA has granted fast track designation for FX-322.
At present, there are no FDA approved medicines for sensorineural hearing loss. In a Phase 1/2 study, FX-322 demonstrated a statistically significant and clinically meaningful improvement in key measures of hearing loss, including clarity of sound and word recognition, with no serious adverse events observed.